TIAA CREF Investment Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

TIAA CREF Investment Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-659	Closed	-$417K	–	3148
2015 Q2	$417K	Sell	659 -242	-27%	-$129K	﹤0.01%	3013
2015 Q1	$464K	Buy	901 +68	+8%	+$34.3K	﹤0.01%	2940
2014 Q4	$446K	Sell	833 -24	-3%	-$10.8K	﹤0.01%	2989
2014 Q3	$1.29M	Sell	857 -11	-1%	-$15.9K	﹤0.01%	2493
2014 Q2	$1.19M	Buy	868 +207	+31%	+$240K	﹤0.01%	2616
2014 Q1	$917K	Buy	661 +51	+8%	+$59.3K	﹤0.01%	2690
2013 Q4	$607K	Hold	610	–	–	﹤0.01%	2904
2013 Q3	$635K	Buy	610 +21	+4%	+$22.4K	﹤0.01%	2862
2013 Q2	$645K	Buy	+589	New	+$656K	﹤0.01%	2840

Other funds holding VIRX

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TIAA CREF Investment Management's VIRX Position: Q3 2015 in Review

TIAA CREF Investment Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2015, closing a stake of 659 shares — an estimated $417K sold.

TIAA CREF Investment Management first reported a position in VIRX in Q2 2013 and held it in 9 quarters. The position peaked at $1.29M in Q3 2014. 59 funds tracked by Wall St. Rank hold VIRX as of Q3 2015.

TIAA CREF Investment Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
TIAA CREF Investment Management sold 659 Viracta Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $417K.
TIAA CREF Investment Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 9 quarters.
TIAA CREF Investment Management's Viracta Therapeutics, Inc. Common Stock position peaked at $1.29M in Q3 2014.
59 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2015.

Based on TIAA CREF Investment Management's 13F filing for Q3 2015, filed 13 Nov 2015.